Respiratory Syncytial Virus Published: September 9, 2024

Executive Summary Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term respiratory sequelae. Recent advances show great promise such as RSV vaccines and monoclonal antibodies. In the first of a Series of four papers, disease burden, clinical management, risk factors, and emerging therapies are discussed for severe RSV infection in children. The second paper reviews possible long-term sequelae, addressing inequities. The third paper focuses on RSV infections in adults, highlighting the neglect of this patient group. The fourth paper discusses RSV vaccination and immunoprophylaxis in young children, as well as exploring potential regulatory, policy, and implementation pathways. It also addresses the health economic evidence to inform product introduction decisions. Evidence reviewed in this Series should help implement preventive strategies to reduce the burden of RSV-related disease in vulnerable populations worldwide. https://www.thelancet.com/series/respiratory-syncytial-virus?dgcid=hubspot_email_conferencealerts_ers24_rsv24&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8ohvq5juZEaL8jE5bLb1RoMmISdi9gGjmWMsWOp_gA8j3A5Sf2UEyod2s_X313tJo_pybhF0G-YLJx1oQNJNNlUcQFyQ&_hsmi=325072833&utm_content=323935440&utm_source=hs_email